NovoCure Limited (NASDAQ:NVCR) Q2 2025 Earnings Conference Call July 25, 2025 8:00 AM ET
Company Participants
Ashley Cordova – CEO & Director
Christoph Brackmann – Chief Financial Officer
Frank Leonard – Executive VP & President of Novocure Oncology
Ingrid Goldberg – VP of Investor Relations
William F. Doyle – Executive Chairman
Conference Call Participants
Emily Claudia Bodnar – H.C. Wainwright & Co, LLC, Research Division
Jason M. Bednar – Piper Sandler & Co., Research Division
Jessica Macomber Fye – JPMorgan Chase & Co, Research Division
Kevin Michael DeGeeter – Ladenburg Thalmann & Co. Inc., Research Division
Lawrence H. Biegelsen – Wells Fargo Securities, LLC, Research Division
Vijay Muniyappa Kumar – Evercore ISI Institutional Equities, Research Division
Wei Ji Chang – Leerink Partners LLC, Research Division
Operator
Good day. Thank you for standing by. Welcome to Novocure’s Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that today’s conference may be recorded.
I will now hand the conference over to your speaker host, Ingrid Goldberg. Please go ahead.
Ingrid Goldberg
Good morning, and thank you for joining us to review Novocure’s second quarter 2025 performance. I’m on the phone this morning with our Executive Chairman, Bill Doyle; CEO, Ashley Cordova; and CFO, Christoph Brackmann. Other members of our executive leadership team will be available for Q&A. For your reference, slides accompanying this earnings release can be found on our website www.novocure.com on the Investor Relations page under Quarterly Reports.
Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements, and actual results could differ materially from those projected in these statements. These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings. We do not intend to update publicly
